Search Results
Jun 01, 2026, 11:11 ET UCB Launches Career-Advancing Scholarship Program for Adults Living with Hidradenitis Suppurativa and Immediate Family Members
Decisions: A Cross-Sectional Study. Indian J Dermatol. 2025;70(5):283-286.Sabat R, Jemec GBE, Matusiak L, et al. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18.Jemec GBE. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158–64.
More news about: UCB
Jun 01, 2026, 09:24 ET Promising Phase 1 Data for Servier's Emiltatug Ledadotin (Emi-Le) in Adenoid Cystic Carcinoma (ACC) Presented at ASCO 2026
the difficult-to-treat rare cancer ACC, most notably demonstrating favorable tolerability and a potentially differentiated safety profile," said Glenn J. Hanna, M.D., study investigator and Director, Center for Cancer Therapeutic Innovation at Dana Farber Cancer Institute. "The encouraging anti-tumor activity
More news about: Servier Pharmaceuticals
Jun 01, 2026, 09:01 ET Veritas Aortic Solutions, an inQB8 Spinout, Raises $12M to Advance Non-Surgical Treatment of Aortic Root and Ascending Aortic Diseases
Nirdesh Gupta PhD (Managing Partner of Cedars-Sinai Intellectual Property Company (CSIPCo)), joined Veritas and inQB8 co-founders, Arshad Quadri, MD and J. Brent Ratz, on the company's Board of Directors."With combined mortality and morbidity rates as high as 65%, it is hard to overstate the risk
More news about: Veritas Aortic Solutions
Jun 01, 2026, 09:00 ET Lossdog Gives New Graduates Access to the Workforce Data Employers Already Rely On
the market prices their skills, credentials, geography, and experience and who can negotiate with data instead of uncertainty," he added.James J. Angel, Ph.D., CFA, CFP®, Associate Professor at McDonough School of Business, Georgetown University, said "Lossdog is a great service that will help
More news about: Lossdog
Jun 01, 2026, 08:52 ET BD&J Achieves Stunning $3 Billion in Recoveries for California Personal Injury Clients
receive as much in compensation as possible to heart. Everyone in the BD&J family – from HR to Paralegals – had a part to play and we're so appreciative of their hard work and our clients' trust."About BD&J, PC: BD&J, PC, has served all Californians for over 20 years in many areas
More news about: BD&J, PC
Jun 01, 2026, 08:34 ET Paradyne AI, a Next Generation AI company, Led by Decorated U.S. Special Operations AI Architect to open in Las Vegas, Nevada
signaled openness to small, strategically aligned private investments.Jamal most recently served as Deputy Director for Intelligence (Deputy J2) at U.S. Special Operations Command Africa, where he led one of the most cutting edge and successful digital ISR program for the Department of War. He
More news about: Paradyne AI
Jun 01, 2026, 08:30 ET Allspring Utilities and High Income Fund
Distributor, LLC (a broker-dealer and Member FINRA/SIPC).© 2026 Allspring Global Investments Holdings, LLC. All rights reserved. ALL-05272026-qnqiuv6j
More news about: Allspring Global Investments
Jun 01, 2026, 08:00 ET USAP Antitrust Case Update: FTC Case Stayed Pending Settlement Agreement in Principle; Patients' Putative Class Action Continues
Bruns LLP; Kellie Lerner, David Scupp, Keagan Potts, and Mike Keramidas of Shinder Cantor Lerner LLP; Kimberly A. Justice, William H. London, Robert J. Wozniak, and Samantha M. Gupta of Justic Jagher London & Millen LLC; and Justin S. Nematzadeh of Nematzadeh PLLC.For more information, please
More news about: Gibbs & Bruns LLP
Jun 01, 2026, 08:00 ET Wockhardt Receives U.S. FDA Approval for ZAYNICH™ (cefepime and zidebactam), a Novel Intravenous Antibiotic for the Treatment of Adult Patients with Complicated Urinary Tract Infection Including Pyelonephritis
https://www.cdc.gov/antimicrobial-resistance/about/index.html3 Marantidis, J., & Sussman, R. D. (2023). Unmet needs in complicated urinary tract infections: Challenges, recommendations, and emerging treatment pathways. Infection
More news about: Wockhardt
Jun 01, 2026, 07:45 ET New Guide Can Assist Modern Day Disciples of Jesus Engage his Central Mission and Closing Prayer, to Live a Life Spiritually One with Him, "Abiding in the Vine"
In "From the Fig Tree to the Vine," author Michael J. Parkyn urges readers to abandon the "fig tree life" of religious striving that has only leaves and no fruit, and rather learn to abide in the vine, just
More news about: WestBow Press
Jun 01, 2026, 07:45 ET Michael Patrick Daly, Former DOJ National Security Official, Joins Cravath
national security and foreign investment matters central to the regulatory process our clients consider when pursuing cross‑border investments," said Faiza J. Saeed, Cravath's Presiding Partner. "We are thrilled to welcome him to Cravath."With the addition of Mr. Daly, Cravath further expands its Washington,
More news about: Cravath, Swaine & Moore LLP
Jun 01, 2026, 06:59 ET Cellulose Ether & Derivatives Market worth $16.47 billion by 2031- Exclusive Report by MarketsandMarkets™
Ltd. (Japan), Nouryon Chemical Holdings B.V. (Netherlands), Shandong Head Co., Ltd. (China), Colorcon (US), FENCHEM (China), Lamberti S.p.A. (US), and J. RETTENMAIER & SÖHNE GmbH + Co KG (Germany) are among the key global manufacturers offering cellulose ethers & their derivatives for a wide range
More news about: MarketsandMarkets
Jun 01, 2026, 06:17 ET Alter Wolff Foley & Stutman LLP Announces Prestigious Recognitions in Family and Matrimonial Law
Jenifer J. Foley,
More news about: Alter Wolff Foley & Stutman LLP
Jun 01, 2026, 04:19 ET Sobi to present new data on pegcetacoplan at ERA 2026
Int. 2012;82(4):454-464.3. Zand L, et al. J Am Soc Nephrol. 2014;25(5):1110-1117.4. Tarragón, B, et al. Clin J Am Soc Nephrol 2024; 19(8)1005-1015.5. Data on file using literature consensus.6. Fakhouri F, et al. N Engl J Med 2025;393:2210-2220CONTACT: Visiting
More news about: Swedish Orphan Biotrauma AB
Jun 01, 2026, 03:54 ET SES AI Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SES
release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1 Eastchester, NY 10709Phone: 914-206-9742Email:
More news about: DJS Law Group LLP
Jun 01, 2026, 03:53 ET Globant S.A. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GLOB
release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1Eastchester, NY 10709Phone: 914-206-9742Email:
More news about: DJS Law Group LLP
Jun 01, 2026, 03:52 ET Upstart Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - UPST
release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1 Eastchester, NY 10709Phone: 914-206-9742Email:
More news about: DJS Law Group LLP
Jun 01, 2026, 03:51 ET Medpace Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MEDP
release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1Eastchester, NY 10709Phone: 914-206-9742 Email:
More news about: DJS Law Group LLP
Jun 01, 2026, 03:50 ET Gossamer Bio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GOSS
release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1Eastchester, NY 10709Phone: 914-206-9742Email:
More news about: DJS Law Group LLP
Jun 01, 2026, 03:50 ET Stellantis N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - STLA
release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1 Eastchester, NY 10709Phone: 914-206-9742Email:
More news about: DJS Law Group LLP
Jun 01, 2026, 03:04 ET China's Original Innovative Drug Cipepofol Approved for Marketing by the U.S. FDA
Aortic Stenosis: A Randomized Clinical Trial. JAMA Surg. 2025;14.9(IF).Yu Y, Deng J, Yin Y,et al. Ciprofol vs propofol for gastrointestinal endoscopy sedation: a systematic review and meta-analysis. Int J Surg. 2025;10.1(IF).He ZZ, Liang JY, Duan JX, et al. Ciprofol versus propofol sedation
More news about: Haisco
May 31, 2026, 17:36 ET Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026
1. Mellinghoff, I. K., van den Bent, M. J., Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J., Mendez, J., Yust-Katz, S., Welsh, L., Mason, W. P., Ducray, F., Umemura, Y., Nabors, B., Holdhoff, M., Hottinger, A. F., Arakawa, Y., Sepulveda, J. M., Wick, W., Soffietti, R., … Cloughesy, T. F.
More news about: Servier Pharmaceuticals
May 31, 2026, 08:29 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
PD-1(PD-L1)-pretreated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Ann Oncol. 2025;36:S1707.7 Fayette J, et al. INTERLINK-1: A Phase III, randomized, placebo-controlled study of monalizumab plus cetuximab in recurrent/metastatic head and neck squamous cell
More news about: Johnson & Johnson
May 31, 2026, 08:27 ET Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
Prostate Cancer. N Engl J Med. 2026. doi:10.1056/NEJMoa2603878.3 Young HH. The early diagnosis and radical cure of carcinoma of the prostate. Being a study of 40 cases and presentation of a radical operation which was carried out in four cases. 1905. J Urol. 2002;168:914-21.
More news about: Johnson & Johnson
May 30, 2026, 08:05 ET ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile® Provides Superior Tumor Control Leading to Patients Living Longer Without Recurrence Compared to Standard of Care in Newly Diagnosed Operable Brain Metastases
[email protected] J. J Clin Oncol 44, 2026 (suppl 17; abstr LBA2000).Lamba N, Wen PT, Aizer AA. Epidemiology of brain metastases and leptomeningeal disease. Neuro-Oncology.
More news about: GT Medical Technologies